DDInter1008 DDInter300
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in a variety of psychiatric disorders, including schizophrenia, bipolar disorders, and major depressive disorder. Cariprazine gained its first global approval in the US in September 2015 and was later approved by Health Canada in April 2022. It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fluconazole
Fluconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is downregulated by {v} (Compound) Vemurafenib
Vemurafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) upregulates {v} (Gene) MSMO1
MSMO1 {u} (Gene) is upregulated by {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is upregulated by {v} (Compound) Alimemazine
Alimemazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) upregulates {v} (Gene) FDFT1
FDFT1 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) is included by {v} (Pharmacologic Class) P-Glycoprotein Inhibitors
P-Glycoprotein Inhibitors {u} (Pharmacologic Class) includes {v} (Compound) Crizotinib
Crizotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) CYP51A1
CYP51A1 {u} (Gene) is bound by {v} (Compound) Miconazole
Miconazole {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cariprazine
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound) and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is downregulated by Vemurafenib (Compound) and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) upregulates MSMO1 (Gene) and MSMO1 (Gene) is upregulated by Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) binds CYP51A1 (Gene) and Ketoconazole (Compound) upregulates CYP51A1 (Gene) and CYP51A1 (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) binds CYP51A1 (Gene) and Ketoconazole (Compound) upregulates CYP51A1 (Gene) and CYP51A1 (Gene) is upregulated by Alimemazine (Compound) and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) upregulates FDFT1 (Gene) and FDFT1 (Gene) is downregulated by Nilotinib (Compound) and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) is included by P-Glycoprotein Inhibitors (Pharmacologic Class) and P-Glycoprotein Inhibitors (Pharmacologic Class) includes Crizotinib (Compound) and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine
Ketoconazole (Compound) binds CYP51A1 (Gene) and Ketoconazole (Compound) upregulates CYP51A1 (Gene) and CYP51A1 (Gene) is bound by Miconazole (Compound) and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Cariprazine